Amylin (AMLN) Wants a Buyout Price At Least in the Low-to-Mid $30s - Jefferies
Tweet Send to a Friend
In late-March, Amylin Pharmaceuticals (NASDAQ: AMLN) rejected a $22 per share takeover bid from Bristol-Myers Squibb (NYSE: BMY). Since ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
